A new atlas of how antibodies attack the spike protein of SARS-CoV-2, the virus that causes COVID-19, could help researchers design more effective vaccines and treatments.
The atlas, published in the journal Nature, is based on data from over 1,000 antibody-spike protein crystal structures. It shows how different antibodies bind to different parts of the spike protein, and how these interactions can affect the virus's ability to infect cells.
"This atlas provides a comprehensive view of how antibodies recognize the spike protein of SARS-CoV-2," said study co-author Jason McLellan, a structural biologist at the University of Texas at Austin. "This information can be used to design vaccines and treatments that are more effective against the virus."
The spike protein is a key part of SARS-CoV-2, and it is the target of most vaccines and treatments that are currently being developed. The protein is located on the surface of the virus, and it is responsible for binding to cells and allowing the virus to enter.
Antibodies are proteins that are produced by the immune system in response to infection. They can bind to viruses and prevent them from infecting cells.
The new atlas shows that antibodies can bind to different parts of the spike protein, including the receptor-binding domain (RBD). The RBD is the part of the spike protein that binds to cells, and it is a key target for vaccines and treatments.
The atlas also shows that some antibodies can bind to multiple parts of the spike protein, which could make them more effective at preventing infection.
"These findings could help us to design more effective vaccines and treatments against SARS-CoV-2," said McLellan. "By targeting the most vulnerable parts of the spike protein, we can develop therapies that can block the virus from infecting cells."
The new atlas is a valuable resource for researchers who are working to develop vaccines and treatments against COVID-19. It provides a comprehensive view of how antibodies interact with the spike protein, and it could help to speed up the development of new therapies.
